Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763

Article  PubMed  Google Scholar 

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825. https://doi.org/10.1056/NEJMoa1011923

Article  CAS  PubMed  Google Scholar 

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703. https://doi.org/10.1056/NEJMoa1304369

Article  CAS  Google Scholar 

Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388:248–257. https://doi.org/10.1016/s0140-6736(16)30583-9

Article  CAS  PubMed  Google Scholar 

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820. https://doi.org/10.1056/NEJMoa072252

Article  CAS  PubMed  Google Scholar 

Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C (2018) S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Ann Oncol 29:624–631. https://doi.org/10.1093/annonc/mdx816

Article  CAS  PubMed  Google Scholar 

Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548–557. https://doi.org/10.1097/00001813-199607000-00010

Article  CAS  PubMed  Google Scholar 

Tatsumi K, Fukushima M, Shirasaka T, Fujii S (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78:748–755

CAS  PubMed  Google Scholar 

Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M (1996) Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56:2602–2606

CAS  PubMed  Google Scholar 

Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53:4004–4009

CAS  PubMed  Google Scholar 

Morimoto Y, Takeuchi O, Takizawa A, Yoneyama H, Asanuma F, Suzuki Y, Atsuda K, Yamada Y (2012) Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines. Anticancer Drugs 23:505–514. https://doi.org/10.1097/CAD.0b013e328350e8c7

Article  CAS  PubMed  Google Scholar 

Morimoto Y, Takada K, Takeuchi O, Takagi A, Watanabe K, Hirohara M, Hamamoto T, Masuda Y (2020) Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S-1. Oncol Rep 43:689–699. https://doi.org/10.3892/or.2019.7421

Article  CAS  PubMed  Google Scholar 

Qiu Z, Oleinick NL, Zhang J (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450–464. https://doi.org/10.1016/j.radonc.2017.09.043

Article  CAS  PubMed  Google Scholar 

Smith HL, Southgate H, Tweddle DA, Curtin NJ (2020) DNA damage checkpoint kinases in cancer. Expert Rev Mol Med 22:e2. https://doi.org/10.1017/erm.2020.3

Article  CAS  PubMed  Google Scholar 

Yano K, Shiotani B (2023) Emerging strategies for cancer therapy by ATR inhibitors. Cancer Sci 114:2709–2721. https://doi.org/10.1111/cas.15845

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5:2000–2005

CAS  PubMed  Google Scholar 

Chou T-C (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440–446. https://doi.org/10.1158/0008-5472.CAN-09-1947

Article  CAS  PubMed  Google Scholar 

Yoshizawa J, Takizawa A, Takeuchi O, Hiraku O, Sasaki K, Morimoto Y, Atsuda K, Inoue G, Suzuki Y, Asanuma F, Yamada Y (2009) Experimental study of combination therapy with S-1 against pancreatic cancer. Cancer Chemother Pharmacol 64:1211–1219. https://doi.org/10.1007/s00280-009-0990-0

Article  CAS  PubMed  Google Scholar 

Nam AR, Jin MH, Bang JH, Oh KS, Seo HR, Oh DY, Bang YJ (2020) Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer. Cancer Res Treat 52:945–956. https://doi.org/10.4143/crt.2020.080

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suzuki K, Takeuchi O, Suzuki Y, Kitagawa Y (2019) Mechanisms of metformin’s anti-tumor activity against gemcitabine-resistant pancreatic adenocarcinoma. Int J Oncol 54:764–772. https://doi.org/10.3892/ijo.2018.4662

Article  CAS  PubMed  Google Scholar 

Goto H, Izawa I, Li P, Inagaki M (2012) Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy? Cancer Sci 103:1195–1200. https://doi.org/10.1111/j.1349-7006.2012.02280.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suzuki T, Hirokawa T, Maeda A, Harata S, Watanabe K, Yanagita T, Ushigome H, Nakai N, Maeda Y, Shiga K, Ogawa R, Mitsui A, Kimura M, Matsuo Y, Takahashi H, Takiguchi S (2022) ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting repair of DNA damage. Oncol Rep 47:78. https://doi.org/10.3892/or.2022.8289

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harata S, Suzuki T, Takahashi H, Hirokawa T, Kato A, Watanabe K, Yanagita T, Ushigome H, Shiga K, Ogawa R, Mitsui A, Kimura M, Matsuo Y, Takiguchi S (2023) AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells. Oncol Rep 49:52. https://doi.org/10.3892/or.2023.8489

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keane F, O’Connor CA, Park W, Seufferlein T, O’Reilly EM (2023) Pancreatic cancer: BRCA targeted therapy and beyond. Cancers (Basel) 15:2955. https://doi.org/10.3390/cancers15112955

Article  CAS  PubMed  Google Scholar 

Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O’Reilly EM, Bordia S, McGuinness D, Cui K, Locker GY, Golan T (2022) Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol 40:3929–3939. https://doi.org/10.1200/jco.21.01604

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kasuga A, Okamoto T, Udagawa S, Mori C, Mie T, Furukawa T, Yamada Y, Takeda T, Matsuyama M, Sasaki T, Ozaka M, Ueki A, Sasahira N (2022) Molecular features and clinical management of hereditary pancreatic cancer syndromes and familial pancreatic cancer. Int J Mol Sci 23:1205. https://doi.org/10.3390/ijms23031205

Article  CAS  PubMed  PubMed Central